Arrowstreet Capital, Limited Partnership Supernus Pharmaceuticals, Inc. Transaction History
Arrowstreet Capital, Limited Partnership
- $120 Billion
- Q1 2025
A detailed history of Arrowstreet Capital, Limited Partnership transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 256,406 shares of SUPN stock, worth $8.37 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
256,406
Previous 174,916
46.59%
Holding current value
$8.37 Million
Previous $6.32 Million
32.78%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding SUPN
# of Institutions
305Shares Held
60.8MCall Options Held
8.8KPut Options Held
6.3K-
Black Rock Inc. New York, NY10.4MShares$339 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.16MShares$201 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$170 Million2.59% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$94.7 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.7MShares$88.1 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.75B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...